North America Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infect

North America Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)

The North America carbapenem-based antibiotics market is expected to reach US$ 1,713.21 million by 2028 from US$ 1,244.59 million in 2021; it is estimated to grow at a CAGR of 4.7% from 2021-2028.

The market's growth is attributed to driving factors such as rising prevalence of bacterial infections and increasing development of generic drugs. However, the tedious and expensive process of the development of antibiotics is expected to restrain the market's growth during the forecast period.

Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTIs and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTIs, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing.

In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.

According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.

North America Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)

NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION

By Type

Meropenem Imipenem Doripenem Tebipenem Others By Indication

Bacterial Meningitis Acute Pelvic Infections Respiratory Tract Infections Intra-Abdominal Infections Urinary Tract Infections Others By Distribution Channel

Hospital Pharmacies Retail Pharmacies Online Pharmacies By Country

US Canada Mexico Company Profiles

ACS Dobfar S.p.A Iterum Therapeutics plc DAEWOONG PHARMACEUTICAL CO., LTD Aurobindo Pharma Ltd Gland Pharma Limited Merck & Co., Inc. Sumitomo Dainippon Pharma Co., Ltd. Savior Lifetec Pfizer Inc. Spero Therapeutics

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America carbapenem-based antibiotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.